Back

Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapy: statins and beyond Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Kunal Mahajan

Himachal Heart Institute, Himachal Pradesh (India)

6 More presentations in this session

Presentation thumbnail
Plasma statin concentrations do not correlate with statin-induced myalgia
Doctor M. Ritvos (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease
Doctor K. Stepien (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Long-term administration of atorvastatin had no effect on the occurrence and progression of spontaneous hypertensive intracerebral hemorrhage in mice
Doctor X. Bian (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Impact of allogenic Fecal Microbiota Transplantation (FMT) on lipid parameters in patients with metabolic syndrome (MetS): a meta-analysis
Doctor L. Wang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy: statins and beyond

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Unmet needs of LDL C lowering in ACS patients when using only high intensity statins puts at setback
thumbnail
Congress Presentation
Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients
thumbnail
Congress Presentation
Efficacy of combination therapy with statin and ezetimibe versus high dose statin monotherapy in secondary prevention in high-risk patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources